Hemerus Medical has announced CE mark approval of its new SOLX red blood cell additive (AS-7), designed to reduce storage lesions and improve the quality of red blood cells.
The 56-day red blood cell storage solution was developed in collaboration with US Army and the US based University of Cincinnati, according to the company.
Hemerus CTO and Leukosep and Leup technologies inventor Dr Majid Zia said that extended red blood cell storage could provide better logistics and mitigate shortages in emergency or natural disaster situations.
"SOLX was developed to reduce storage lesions and improve the quality of red blood cells through the current standard 42 day storage period," Zia said.
"This is extremely important as enhanced red cell quality is of great interest in potentially improving patient outcomes in transfusions."
Hemerus Medical CEO Michael Spearman said the SOLX storage solution can now be commercialised throughout most of the world.
"We are looking forward to also receiving the FDA approval so it will be available in the US as well," Spearman said.
In addition to the CE mark approval, the company is in negotiations to be acquired by Haemonetics, a provider of blood management solutions.
Under the transaction, Haemonetics will pay up to $27m in several stages Hemerus, apart from an additional payment of up to $14m based on future sales of SOLX products.
Haemonetics president and CEO Brian Concannon said the addition of Hemerus’ SOLX collection system complements the portfolio of whole blood collection, filtration and processing product lines, which the company recently acquired from Pall.
"We will proceed with the Haemonetics and Pall elements of that offering while the FDA examination process for the SOLX solution continues," Concannon said.